SPARC · Sun Pharma Advanced Research Company Ltd · Biotechnology & Drugs
SPARC · Sun Pharma Advanced Research Company Ltd · Biotechnology & Drugs
As of 05 Nov close
52-week range
32.1% below 52-week high
52-week range: as of 05 Nov 2026 close.
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 16 Oct 2026
Revenue (latest Q)
₹40 Cr
Revenue YoY
PAT YoY
+59.9%
Operating margin
Revenue, last 5 quarters
Source: Yahoo Finance, as of 30 Jun 2026
P/E (TTM)
P/B
4.4
P/S (TTM)
Not available from data source
Sector P/E
Not available from data source
Dividend yield
Not available from data source
Source: Yahoo Finance, as of 29 Oct 2026
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| SPARC (this stock) | 3.8 | 4.4 | +83.0% | +116.0% | 0.42 | Not available from data source |
| Sun Pharmaceutical Industries | 36.6 | 5.3 | Not available from data source | Not available from data source | Not available from data source | Not available from data source |
| Divi's Laboratories * | 59.7 | 14.5 | +26.1% | +17.4% | 0 | +0.3% |
| Torrent Pharmaceuticals | 75.8 | 20 | Not available from data source | Not available from data source | Not available from data source | Not available from data source |
* Net margin, ROE, D/E and dividend yield for these companies come from RedixFi fundamentals; the data vendor had no values for them.
Promoter
stable
FII
falling 1q
MF
0.10% (+0.02pp)
stable
Insider trades
| Date | Insider | Type | Qty | Value |
|---|---|---|---|---|
| 19 May 2026 | Shanghvi Finance Private Limited | BUY | 3,85,10,000 | ₹150 Cr |
Bulk/block deals
| canonicalSymbol | date | buy quantity | buyer count | deal strength | deal types present |
|---|---|---|---|---|---|
| SPARC | 2026-05-26 | 1986488 | 1 | WEAK | BULK |
| SPARC | 2026-05-25 | 11108154 | 5 | WEAK | BULK |
| SPARC | 2026-05-01 | 0 | 0 | STRONG | BULK |
| SPARC | 2026-04-30 | 0 | 0 | STRONG | BULK |
News timeline
No related news.
Concalls & investor presentations
AI-generatedNo concall transcripts or investor presentations recorded yet.
AI Summary of Annual Report
AI-generatedSun Pharma Advanced Research Company Limited (SPARC) reported significant financial losses for the third consecutive year, leading to no obligation for CSR activities. The company has no public deposits, and its credit rating remains ACUITE AA- with a stable outlook. SPARC is focused on R&D with ongoing projects like SBO-154 and SCD-153, and has no material defaults or regulatory penalties. The auditor highlighted revenue recognition and tax litigation as key audit matters, but no material uncertainties about going concern were noted. The company has no pending insolvency cases or material disputes.
- SPARC incurred losses for three consecutive years, exempting it from CSR obligations.
- No public deposits accepted, and credit rating remains ACUITE AA- with stable outlook.
- R&D focus with projects like SBO-154 and SCD-153 in development.
- No material defaults, regulatory penalties, or insolvency proceedings noted.
- Auditor identified revenue recognition and tax litigation as key audit matters.
Key takeaway: SPARC continues R&D efforts despite three-year losses, with no major defaults or regulatory issues, but faces risks from tax litigations and financial sustainability.
The following annual report excerpts provide qualitative strategic context. Do not treat any specific financial figures in these excerpts as authoritative — they may be incorrectly labeled due to PDF table extraction limitations. For precise financial data, refer to the structured fundamentals data above.
Governance disclosures
AI-generatedNeeds attention
No item of a kind that needs attention was stored for this company.
Contingent Liability
2 occurrencesEarlier (1-3 years ago)
The company has disputed demands by Income tax authorities amounting to ₹3,241.14 Lakhs as at March 31, 2025, and disputed demands by Service tax authorities amounting to ₹172.65 Lakhs as at March 31, 2025.
The company has a contingent liability of ₹2,700 lakhs payable to Sun Pharmaceutical for the paused SCO-120 program.
Related-Party Transaction
2 occurrencesEarlier (1-3 years ago)
The Group has an outstanding corporate guarantee from Shanghvi Finance Private Limited amounting to ₹20,000 Lakhs as at March 31, 2025.
Sun Pharmaceutical Industries Limited has an outstanding corporate guarantee from Shanghvi Finance Private Limited amounting to 20,000 Lakhs as at March 31, 2024.
Promoter Share Pledge
1 occurrenceRecent (last 12 months)
2.85% of promoter holding pledged (quarter 2026-Q3 as of 2026-07-18). Change vs the previous disclosure: decreasing.